Management of variceal bleeding

Current Opinion in Critical Care

Volumn 8, Issue 2, 2002, Pages 164-170

  Harry, Rachael ^a   Wendon, Julia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CYANOACRYLATE; GLYCERYL TRINITRATE; IRBESARTAN; ISOSORBIDE MONONITRATE; LOSARTAN; NADOLOL; NITRATE; OCTREOTIDE; PROPRANOLOL; SCLEROSING AGENT; SOMATOSTATIN; SUCRALFATE; TERLIPRESSIN; VAPREOTIDE; VASOPRESSIN;

BETA ADRENERGIC RECEPTOR BLOCKING; BLEEDING; CLINICAL TRIAL; EMERGENCY TREATMENT; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; ENDOSCOPY; HUMAN; INFECTION; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; LIVER SURGERY; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIMARY PREVENTION; RESUSCITATION; REVIEW; SALVAGE THERAPY; SECONDARY PREVENTION; TUBE; VASCULAR DISEASE;

ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 0036965910     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200204000-00013     Document Type: Review

References (47)

1. Vorobioff J, Bredfeldt J, Groszmann R: Hyperdynamic circulation in portal hypertensive rat model: a primary factor for the maintenance of chronic portal hypertension. Am J Physiol 1983, 244:G52-G57.
2. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices: Predictors of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective, multicenter trial. N Engl J Med 1988, 319:983-989.
3. Baker L, Smith C, Liebermann, G: The natural history of esophageal varices. Am J Med 1959, 26:288-237.
4. Christensen E, Fauerholdt L, Schlichtong P: Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 1981, 81:944-952.
5. Merkel C, Bolognesi M, Sacerdoti D, et al.: The haemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000, 32:930-934.
6. Hayes P, Davies J, Lewis J, et al.: Meta analysis of the value of propranolol in the prevention of variceal hemorrhage. Lancet 1990, 336:153-166.
7. Garcia-Pagan J, Villanueva C, Vila M, et al.: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot tolerate β-blockers. Gastroenterology 2001, 121:908-914. • A double-blind, randomized, controlled study refuting the role of isosorbide mononitrate in primary prophylaxis of variceal bleed as monotherapy in those intolerant of β-blockers.
8. Angelico M, Carli L, Plat C, et al.: Effects of isosorbide-5 mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997, 113:1632-1639.
9. Merkel C, Marin R, Sacerdoti D, et al.: Long term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000, 31:324-329.
10. Imperiale T, Chalasani N: A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001, 33:802-807. •• A meta-analysis of five trials and 601 patients demonstrating a place for esophageal banding in the primary prophylaxis of variceal bleeding.
11. Benoit JN, Womack WA, Korthius RJ, et al.: Chronic portal hypertension: effects on gastrointestinal blood flow distribution. Am J Physiol 1986, 250:G535-G539.
12. Vlavianos P, MacMathuna P, Williams R, et al.: Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension. Clin Sci 1997, 96:475-481.
13. Bernard B, Cadranel J-F, Valla D, et al.: Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995, 108:1828-1834.
14. Goulis J, Armonis A, Patch D, et al.: Bacterial infection is independently associated with failure to control breeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998, 27:1207-1212.
15. Goulis J, Patch D, Burroughs A: Bacterial infection in the pathogenesis of variceal bleeding. 1999, 353:139-142.
16. Bernard B, Grange J-D, Nyugen Khac E, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655-1661.
17. Gimson A, Westaby D, Hegarty J, et al.: A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986, 6:410-413.
18. Escorsell A, Ruiz del Arbol L, Planas R, et al.: Multicenter, randomised controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST Study. Hepatology 2000, 32:471-476. • A multicenter, randomized study of a considerable number of patients demonstrating equivalence between sclerotherapy and the vasopressin analogue terlipressin in the treatment of acute variceal hemorrhage.
19. Fort E, Sautereau D, Silvaine C, et al.: A randomized trial of terlipressin plus nitroglycerin versus balloon tamponade in the control of acute variceal hemorrhage. Hepatology 1990, 11:678-681.
20. Villanueva C, Ortiz J, Minana J, et al.: Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001, 121:110-117.
21. Imperiale T, Teran J, McCullough AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995, 109:1289-1294.
22. Gotzsche P, Gjorup I, Bonnen H, et al.: Somatostatin vs placebo in bleeding esophageal varices: randomised trial and meta-analysis. BMJ 1995, 310:1495-1498.
23. Bosch J, Lebrec D, Jenkins S: Development of analogues: successes and failures. Scand J Gastroenterol 1998, 33(suppl 226):3-13.
24. Escorsell A, Bandi J, Andreu V, et al.: Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001, 120:161-169.
25. Corley D, Cello J, Adkisson W, et al.: Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001, 120:946-954. •• A meta-analysis of 13 studies of the effect of octreotide in acute variceal bleeding, suggesting that octreotide is a valuable adjunct to endoscopic therapy.
26. Cales P, Masliah C, Bernard B, et al.: Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001, 344:23-28.
27. Eriksson L, Kagedal B, Wahren J: Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med 1984, 76:66-70.
28. Schneider A, Kalk J, Klein C: Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999, 29:334-339.
29. Schepke M, Werner E, Beicker E, et al.: Haemodynamic effects of the angiotensin II receptor antagonist, ibersartan, in patients with cirrhosis and portal hypertension. Gastroenterology 2001, 121:389-395. •• A randomized, placebo-controlled study of irbesartan, an angiotensin II receptor antagonist, in patients with cirrhosis with portal hypertension. Irbesartan demonstrated no effect on portal pressure but a considerable reduction in arterial blood pressure, which suggests that this is not an advisable drug in these patients.
30. Gonzales-Abraldes J, Albillos A, Banares R, et al.: Randomized comparison of long term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001, 121:382-388. •• A randomized comparison of effects of propranolol and losartan, an angiotensin II antagonist, in the secondary prophylaxis of variceal bleeding. After 6 weeks of treatment, losartan did not reduce portal pressure but decreased blood pressure and renal function. Therefore, it is not an alternative to β-blockade.
31. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Int Med 1995, 123:280-287.
32. Ramond M, Valla D, Mosnier J, et al.: Successful endoscopic obliteration of gastric varices with butyl cyanoacrylate. Hepatology 1989, 10:488-493.
33. Lo G-H, Lai K-H, Cheung J-S, et al.: A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001, 33:1060-1064. •• A prospective, randomized study showing improved control of bleeding and survival using cyanoacrylate glue rather than variceal banding in the treatment of gastric varices.
34. Maluf-Filho F, Sakai P, Ishioka S, et al.: Endoscopic sclerosis versus cyano-acrylate endoscopic injection for the first episode of variceal bleeding: a prospective, controlled, and randomised study in Child-Pugh class C patients. Endoscopy 2001, 33:421-427.
35. Azoulay D, Castaing D, Majno P, et al.: Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 2001, 35:590-597. •• A report of the use of TIPS as salvage therapy in 58 patient with variceal bleeding, demonstrating control of bleeding and 1-year survival of 52% despite a high proportion of patients with Child-Pugh B or C cirrhosis, supporting TIPS in these patients.
36. Bizollon T, Dumortier J, Jouisse C, et al.: Transjugular intrahepatic portosystemic shunt for refractory variceal bleeding. Eur J Gastroenterol Hepatol 2001, 13:369-375.
37. Henderson J, Nagle A, Curtas S, et al.: Surgical shunts and tips for variceal decompression in the 1990s. Surgery 2000, 128:540-547.
38. Jalan R, John T, Redhead T, et al.: A comparison of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 1995, 90:1932-1937.
39. Graham D, Smith J: The course of patients after variceal hemorrhage. Gastroenterology 1981, 80:800-809.
40. Lebrec D, Poynard T, Bernuau J, et al.: A randomized controlled study of propranolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. Hepatology 1984, 4:355-358.
41. Bernard B, Lebrec D, Mathurin P, et al.: Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis. Hepatology 1997, 25:63-70.
42. Gournay J, Masliah C, Martin T, et al.: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal bleeding. Hepatology 2000, 31:1239-1245.
43. Villanueva C, Minana J, Ortiz J, et al.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001, 345:647-655. •• A well conducted, randomized trial of endoscopic ligation alone versus medical therapy alone with 72 patients after variceal hemorrhage in each group. The trial reports reduced rebleeding in the medically treated patients, with fewer complications but no difference in mortality over a period of 21 months.
44. Lo G-H, Lai K-H, Cheng J-S, et al.: Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000, 32:461-465.
45. Pomier-Layrargues G, Villeneuve J-P, Deschenes M, et al.: Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001, 48:390-396. •• A randomized study of TIPS versus band ligation in the secondary prophylaxis of variceal bleeding, demonstrating reduced bleeding with TIPS but no increase in encephalopathy despite advanced disease. Survival was the same and days in the hospital were similar during the follow-up period in two groups.
46. Narahara Y, Kanazawa H, Kawamata H, et al.: A randomized clinical trial comparing transjugurar intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatol Res 2001, 21:189-198. • A randomized trail comparing TIPS with sclerotherapy in secondary prophylaxis after variceal bleed demonstrates similar rebleeding and mortality but increased rehospitalization in TIPS group as a result of shunt dysfunction. This finding casts doubt on the role of TIPS in secondary prophylaxis.
47. Helton W, Maves R, Wicks K, et al.: Transjugular intrahepatic portosystemic shunt vs surgical shunt in good risk cirrhotic patients. Arch Surg 2001, 136:17-20. • A retrospective, case-control study in patients with compensated cirrhosis, demonstrating better effectiveness and durability for surgical shunt than TIPS in this patient group, emphasizing the potential role for this often overlooked treatment option.